Nanotrap-enabled quantification of KRAS-induced peptide hydroxylation in blood for cancer early detection

Zaian Deng, Zhen Zhao, Bo Ning, Jeffery Basilio, Karen Mann, Jie Fu, Yajun Gu, Yuanqing Ye, Xifeng Wu, Jia Fan, Paul Chiao, Ye Hu

Research output: Contribution to journalArticle

Abstract

Circulating peptide is a potential source of biomarkers for cancer detection. However, the existence of large molecular weight proteins in plasma have a disastrous effect on circulating peptides isolating and detecting. Herein, nanotrap fractionation following by mass spectrometry have been applied to quantify the levels of bradykinin (BK) and hydroxylated bradykinin (Hyp-BK) as a relative measure of KRAS-regulated Prolyl-4-hydroxylase alpha-1 (P4HA1) which may serve as early diagnosis marker for pancreatic ductal adenocarcinoma (PDAC). We found that P4HA1 can be upregulated by KRAS G12V , which is a PDAC driver mutation, using HPNE/KRAS and HPNE cells. And we revealed that P4HA1 is overexpressed in PDAC tumors, compared to normal and inflamed pancreatic tissues. RNA interference revealed that P4HA1 activity was primarily responsible for Hyp-BK production. Mass spectrometry analysis revealed that plasma Hyp-BK/BK ratio was higher in PDAC than pancreatitis patients and healthy controls, while the area under the receiver operating characteristic (ROC) curve (AUC) is 0.8209 (95%CI, 0.7269–0.9149). The Hyp-BK/BK association with PDAC was reproduced in another cohort, where this ratio was found to increase with advancing tumor stage. These novel findings paved the way for wider applications of Nanotrap coupled mass spectrometry as a powerful tool for revealing biosignatures from plasma.[Figure not available: see fulltext.].

Original languageEnglish (US)
JournalNano Research
DOIs
StatePublished - Jan 1 2019

Fingerprint

Hydroxylation
Bradykinin
Peptides
Blood
Prolyl Hydroxylases
Mass spectrometry
Plasmas
Tumors
Biomarkers
Tumor Biomarkers
Fractionation
RNA
Molecular weight
Association reactions
Tissue
Proteins

Keywords

  • bradykinin
  • hydroxylation level
  • nanotrap
  • pancreatic ductal adenocarcinoma

ASJC Scopus subject areas

  • Materials Science(all)
  • Electrical and Electronic Engineering

Cite this

Nanotrap-enabled quantification of KRAS-induced peptide hydroxylation in blood for cancer early detection. / Deng, Zaian; Zhao, Zhen; Ning, Bo; Basilio, Jeffery; Mann, Karen; Fu, Jie; Gu, Yajun; Ye, Yuanqing; Wu, Xifeng; Fan, Jia; Chiao, Paul; Hu, Ye.

In: Nano Research, 01.01.2019.

Research output: Contribution to journalArticle

Deng, Zaian ; Zhao, Zhen ; Ning, Bo ; Basilio, Jeffery ; Mann, Karen ; Fu, Jie ; Gu, Yajun ; Ye, Yuanqing ; Wu, Xifeng ; Fan, Jia ; Chiao, Paul ; Hu, Ye. / Nanotrap-enabled quantification of KRAS-induced peptide hydroxylation in blood for cancer early detection. In: Nano Research. 2019.
@article{178f16978a074145929626d5d103a15b,
title = "Nanotrap-enabled quantification of KRAS-induced peptide hydroxylation in blood for cancer early detection",
abstract = "Circulating peptide is a potential source of biomarkers for cancer detection. However, the existence of large molecular weight proteins in plasma have a disastrous effect on circulating peptides isolating and detecting. Herein, nanotrap fractionation following by mass spectrometry have been applied to quantify the levels of bradykinin (BK) and hydroxylated bradykinin (Hyp-BK) as a relative measure of KRAS-regulated Prolyl-4-hydroxylase alpha-1 (P4HA1) which may serve as early diagnosis marker for pancreatic ductal adenocarcinoma (PDAC). We found that P4HA1 can be upregulated by KRAS G12V , which is a PDAC driver mutation, using HPNE/KRAS and HPNE cells. And we revealed that P4HA1 is overexpressed in PDAC tumors, compared to normal and inflamed pancreatic tissues. RNA interference revealed that P4HA1 activity was primarily responsible for Hyp-BK production. Mass spectrometry analysis revealed that plasma Hyp-BK/BK ratio was higher in PDAC than pancreatitis patients and healthy controls, while the area under the receiver operating characteristic (ROC) curve (AUC) is 0.8209 (95{\%}CI, 0.7269–0.9149). The Hyp-BK/BK association with PDAC was reproduced in another cohort, where this ratio was found to increase with advancing tumor stage. These novel findings paved the way for wider applications of Nanotrap coupled mass spectrometry as a powerful tool for revealing biosignatures from plasma.[Figure not available: see fulltext.].",
keywords = "bradykinin, hydroxylation level, nanotrap, pancreatic ductal adenocarcinoma",
author = "Zaian Deng and Zhen Zhao and Bo Ning and Jeffery Basilio and Karen Mann and Jie Fu and Yajun Gu and Yuanqing Ye and Xifeng Wu and Jia Fan and Paul Chiao and Ye Hu",
year = "2019",
month = "1",
day = "1",
doi = "10.1007/s12274-019-2405-9",
language = "English (US)",
journal = "Nano Research",
issn = "1998-0124",
publisher = "Press of Tsinghua University",

}

TY - JOUR

T1 - Nanotrap-enabled quantification of KRAS-induced peptide hydroxylation in blood for cancer early detection

AU - Deng, Zaian

AU - Zhao, Zhen

AU - Ning, Bo

AU - Basilio, Jeffery

AU - Mann, Karen

AU - Fu, Jie

AU - Gu, Yajun

AU - Ye, Yuanqing

AU - Wu, Xifeng

AU - Fan, Jia

AU - Chiao, Paul

AU - Hu, Ye

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Circulating peptide is a potential source of biomarkers for cancer detection. However, the existence of large molecular weight proteins in plasma have a disastrous effect on circulating peptides isolating and detecting. Herein, nanotrap fractionation following by mass spectrometry have been applied to quantify the levels of bradykinin (BK) and hydroxylated bradykinin (Hyp-BK) as a relative measure of KRAS-regulated Prolyl-4-hydroxylase alpha-1 (P4HA1) which may serve as early diagnosis marker for pancreatic ductal adenocarcinoma (PDAC). We found that P4HA1 can be upregulated by KRAS G12V , which is a PDAC driver mutation, using HPNE/KRAS and HPNE cells. And we revealed that P4HA1 is overexpressed in PDAC tumors, compared to normal and inflamed pancreatic tissues. RNA interference revealed that P4HA1 activity was primarily responsible for Hyp-BK production. Mass spectrometry analysis revealed that plasma Hyp-BK/BK ratio was higher in PDAC than pancreatitis patients and healthy controls, while the area under the receiver operating characteristic (ROC) curve (AUC) is 0.8209 (95%CI, 0.7269–0.9149). The Hyp-BK/BK association with PDAC was reproduced in another cohort, where this ratio was found to increase with advancing tumor stage. These novel findings paved the way for wider applications of Nanotrap coupled mass spectrometry as a powerful tool for revealing biosignatures from plasma.[Figure not available: see fulltext.].

AB - Circulating peptide is a potential source of biomarkers for cancer detection. However, the existence of large molecular weight proteins in plasma have a disastrous effect on circulating peptides isolating and detecting. Herein, nanotrap fractionation following by mass spectrometry have been applied to quantify the levels of bradykinin (BK) and hydroxylated bradykinin (Hyp-BK) as a relative measure of KRAS-regulated Prolyl-4-hydroxylase alpha-1 (P4HA1) which may serve as early diagnosis marker for pancreatic ductal adenocarcinoma (PDAC). We found that P4HA1 can be upregulated by KRAS G12V , which is a PDAC driver mutation, using HPNE/KRAS and HPNE cells. And we revealed that P4HA1 is overexpressed in PDAC tumors, compared to normal and inflamed pancreatic tissues. RNA interference revealed that P4HA1 activity was primarily responsible for Hyp-BK production. Mass spectrometry analysis revealed that plasma Hyp-BK/BK ratio was higher in PDAC than pancreatitis patients and healthy controls, while the area under the receiver operating characteristic (ROC) curve (AUC) is 0.8209 (95%CI, 0.7269–0.9149). The Hyp-BK/BK association with PDAC was reproduced in another cohort, where this ratio was found to increase with advancing tumor stage. These novel findings paved the way for wider applications of Nanotrap coupled mass spectrometry as a powerful tool for revealing biosignatures from plasma.[Figure not available: see fulltext.].

KW - bradykinin

KW - hydroxylation level

KW - nanotrap

KW - pancreatic ductal adenocarcinoma

UR - http://www.scopus.com/inward/record.url?scp=85064939826&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85064939826&partnerID=8YFLogxK

U2 - 10.1007/s12274-019-2405-9

DO - 10.1007/s12274-019-2405-9

M3 - Article

AN - SCOPUS:85064939826

JO - Nano Research

JF - Nano Research

SN - 1998-0124

ER -